Remap Consulting

🎉 Please join us in welcoming Mariam Bibi to the Remap Consulting team as Practice Lead! “Mariam's vast experience and passion for fostering a collaborative and inclusive environment will greatly enhance our team's capabilities and client offerings. We look forward to the valuable insights and leadership she will bring," said Paul, Managing Director. 👋 Feel free to connect and say hello at Mariam@remapconsulting.com and view her profile. #marketaccess #healthcare #pharmaceutical #consultancyservices #newcareer #newbeginnings #careerdevelopment #mentoring

Do you find the #HTA process for orphan drugs challenging? 🧬 From navigating limited clinical evidence to demonstrating cost-effectiveness, we explore strategic approaches and key considerations that can make a difference in securing HTA approval. If you're involved in rare disease drug development and looking to better understand how to achieve HTA success, this is a must-read! 💡 📅 We'll be attending the World Orphan Drug Congress in Barcelona this October and welcome the opportunity to discuss how Remap Consulting can support you in gaining HTA approval for your rare and orphan products. Connect with Kate Noble at katenoble@remapconsulting.com today. #OrphanDrugs #RareDiseases #HTAApproval #MarketAccess #WODC #RemapConsulting #Healthcare #PatientAccess

🌟 Big news at Remap Consulting! 🌟 We’re thrilled to welcome five fantastic new team members to our growing team! 🎉 👋 Say hello to Richard Sloggett, Amy Boyers, Amrit Kaliasethi, Ella Odams, and Kacper Swierk! Each brings fresh perspectives, valuable expertise, and a shared passion for driving positive change in the world of #marketaccess. As we mark a decade of growth, we're grateful for the unique skills and commitment each team member brings, helping us continue to provide the best support for our partners. Get to know more about them here 👉 https://lnkd.in/e5-THY9Y 🌱 𝐏𝐚𝐬𝐬𝐢𝐨𝐧𝐚𝐭𝐞 𝐚𝐛𝐨𝐮𝐭 𝐦𝐚𝐤𝐢𝐧𝐠 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞? A problem-solver looking for a challenge? Love the #pharma industry? Send us a message to learn about exciting opportunities! #healthcare #teamwork #newbeginnings #careers #pharmalife #remapconsulting #welcometotheteam

Have you heard? 👂 The NICE - National Institute for Health and Care Excellence has reached an incredible milestone with its 1000th #technologyappraisal, approving Iptacopan for paroxysmal nocturnal haemoglobinuria (PNH). This landmark achievement reflects NICE's ongoing commitment to ensuring that patients in the UK have access to the most effective and value-driven treatments. Iptacopan's approval is a significant step forward in patient care, offering a more convenient, oral alternative to traditional intravenous therapies. This innovation not only addresses unmet needs in the treatment of PNH but also enhances patient quality of life. For pharmaceutical companies, this appraisal underscores the importance of developing treatments that deliver strong clinical outcomes while being cost-effective and patient-friendly. The emphasis on robust clinical and economic evidence by #NICE highlights the evolving landscape of healthcare, where balancing effectiveness, convenience, and cost is more crucial than ever. Looking for more insights? Take a look today ➡ https://lnkd.in/ee7u5_gQ #Healthcare #RareDiseases #PatientCare #Pharma #MarketAccess #PatientAccess #NHS #LifeSciences

Barcelona is calling (again!) ☀️ We're excited to join the leading global event dedicated to the advancement of #orphandrugs and #rarediseases. This is our third year at #WODC and our first as a sponsor! In this ever-changing healthcare landscape, staying at the forefront of the latest developments and access strategies is crucial. We're proud to support pharma and biotech companies in navigating the complexities of improving patient access to vital treatments. It's all about working together to make a difference for those affected by rare diseases. Got orphan drugs on your mind? Us too! We'll be hosting a panel discussion on day 2 in the Access & Pricing track—we can't wait to reveal more soon, so stay tuned! 👀 🤝 We're here to help. Let's connect in Spain. Email katenoble@remapconsulting.com to set up a conversation. #MarketAccess #GlobalConference #Pharma #RealWorldEvidence #HTA s #PatientAccess World Orphan Drug Congress Europe

🔍 How can pharma companies optimise drug launches? Our latest article explores how cross-functional collaboration and evidence-based strategies can drive market success, optimise resources, and improve patient outcomes. Click below to read ⤵ #Pharmaceuticals #MarketAccess #EvidenceBasedMedicine #HealthcareStrategy #DrugDevelopment #RealWorldEvidence

The approval of Lecanemab (Biogen/Eisai) marks a ground-breaking moment in the treatment of Alzheimer's disease (AD). It is the first drug proven to slow the progression of AD to be authorised in the UK. With nearly one million people in the UK living with dementia, the majority of whom have Alzheimer's, the implications of this approval are profound. 🧠 ❌ However, Lecanemab faces a significant hurdle: it has 𝐧𝐨𝐭 𝐛𝐞𝐞𝐧 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 by the NICE - National Institute for Health and Care Excellence for use on the #NHS. Lecanemab's approval is grounded in compelling data from the Clarity AD trial, where the drug showed a 𝟐𝟕% 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐜𝐥𝐢𝐧𝐞 compared to a placebo over 18 months. Administered bi-weekly via intravenous infusion, Lecanemab targets amyloid beta plaques in the brain—one of the hallmarks of Alzheimer's—thereby slowing cognitive decline in patients with mild cognitive impairment or mild dementia. Despite these promising clinical outcomes, NICE has cited the small benefits relative to the 𝐡𝐢𝐠𝐡 𝐜𝐨𝐬𝐭𝐬 as a barrier to recommending the drug for NHS use. The treatment not only involves the cost of the drug but also requires substantial infrastructure for regular hospital infusions and intensive monitoring to manage potential side effects. 🗓️ The public consultation on the draft NICE guidance is set for 20 September 2024. Final recommendations are anticipated after a second committee meeting later this year. 𝐍𝐈𝐂𝐄'𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐚 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐢𝐬𝐬𝐮𝐞: balancing the promise of innovative therapies with the economic constraints of the healthcare system. It is not enough to demonstrate clinical efficacy; there must also be a compelling case for cost-effectiveness. This situation prompts a crucial question: How can companies continue developing advanced therapies if they are deemed not cost-effective? This brings to light important discussions about the sustainability of current reimbursement models. There is an urgent need to explore innovative mechanisms for reimbursement to ensure that patients are not left without access to potentially life-changing therapies. 🏥💡 Find more insights online ➡ https://lnkd.in/ee7u5_gQ #AlzheimersDisease #HealthcareInnovation #Pharma #NICE #DrugApproval #HealthcareEconomics #PatientAccess #Biotech #CostEffectiveness #Dementia #MedicalResearch #ReimbursementModels #HealthPolicy #FutureOfHealthcare

Will we see you at #ISPOREurope in Barcelona? 🌍 We're excited to join the leading global conference for health economics and outcomes research (HEOR), where experts from around the world gather to discuss the vital role of scientific evidence in enhancing global health and well-being Since our first ISPOR conference in Amsterdam back in 2014, we've found this event to be a highlight of our year. It's always inspiring to connect, collaborate, and share insights with industry leaders and peers. This year, we have some exciting plans in store and can't wait to reveal more soon—stay tuned! 👀 🤝 If you'd like to arrange a meeting with us at the conference, feel free to email katenoble@remapconsulting.com. #MarketAccess #HEOR #GlobalConference #ISPOR #HealthEconomics #Pharma #RealWorldEvidence #HTA ISPOR—The Professional Society for Health Economics and Outcomes Research

🌍 Ready to master the #EUHTA era? The landscape of EU Health Technology Assessment (HTA) is shifting fast, and the key to success lies in how well you adapt. Whether you're navigating joint clinical assessments, optimising PICOs, or participating in joint scientific consultations, having the right guidance is crucial. In the snippet below, managing directors Graham and Paul discuss the importance of communicating value at the European level. If you missed the live session, don't worry—we've got you covered. Watch our webinar on demand and learn how to seamlessly integrate EU HTA considerations into your long-term strategies, ensuring your organisation stays ahead of the curve 🛣 📽️ Watch the webinar now: https://lnkd.in/ewYuC4s8 #MarketAccess #HEOR #HealthcareStrategy #PICO #JointClinicalAssessments #JointScientificConsultations #HTA #Pharma

⌛ The #EUHTA process is launching with the most complex health technologies—now is the time to act. In our latest article, we delve into the key strategies pharmaceutical manufacturers must adopt to structure market access teams effectively. From defining clear processes and ensuring resource adequacy to fostering impactful cross-functional collaboration, we've got you covered. ⬇ 𝐂𝐥𝐢𝐜𝐤 𝐛𝐞𝐥𝐨𝐰 𝐭𝐨 𝐫𝐞𝐚𝐝, or visit our website 🖥 https://lnkd.in/e4DWnbKZ #MarketAccess #Pharma #EUHTA #HealthcareInnovation #HTA #Pharmaceuticals #RegulatoryAffairs #HealthcareStrategy #JCA